10th Jan 2011 08:51
10 January 2011
Biofutures International plc
("Biofutures" or "the Company")
Board Appointment
The Board of Biofutures International plc (AIM: BIP.L), a UK investment company which invests in the energy and utility sectors and their related infrastructures in Europe, Asia and the Middle East, is pleased to announce the appointment of Clive Robert Purdy as Finance Director of the Company, with immediate effect. Mr Purdy was appointed Company Secretary of Biofutures in June 2010.
Clive (51) studied at the University of Kent where he was awarded a Bachelor of Arts degree in Accounting in 1980. He trained at Peat Marwick Mitchell (now KPMG) where he qualified as a Chartered Accountant in 1983. In 1984 Clive then joined Rowland Hall & Co where he was a junior partner for 7 years, before joining Mudd & Co as a senior partner in 1991. In 1996 Clive qualified as a Licensed Insolvency Practitioner which he later utilised in his role as an Insolvency Director in 2000 at Morrison Stoneham (subsequently taken over by Tenon Group Plc). He is currently a director and a fifty per cent. shareholder of DeVines Accountants Limited, previously known as West-Webbe & Co.
Commenting on Clive's appointment, David Yeoh, the Executive Chairman said:
"We are delighted to welcome Clive to the Board where his skills and experience will assist the Company to further develop its strategy and streamline its operations".
For further information, please contact:
Biofutures International plc | Tel: + 6012 315 0626 |
Joe Wong, Chief Executive Officer | |
www.biofuturesplc.com
| |
Daniel Stewart & Company plc | Tel: + 44 (0) 20 7776 6550 |
Oliver Rigby/Antony Legge (Nomad) Colin Rowbury (Broker) | |
www.danielstewart.co.uk
|
Additional Disclosures
Clive holds, or has held, the following directorships and partnerships within the past five years:
Current directorships / partnerships:
DeVines Accountants Limited
Orsett Masonic Hall Limited
Atherton Bailey LLP
Past directorships / partnerships:
West-Webbe Limited
Save for the information disclosed above there is no other information to be disclosed under schedule two, paragraph (g) of the AIM Rules.
Related Shares:
Graphene Nanochem